Empirical Asset Management’s Filana Therapeutics FLNA Stock Holding History

Empirical Asset Management’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,000	Closed	-$18.1K	–	397
2025 Q2	$18.1K	Hold	10,000	–	–	0.01%	313
2025 Q1	$15K	Hold	10,000	–	–	0.01%	301
2024 Q4	$23.6K	Hold	10,000	–	–	0.01%	416
2024 Q3	$294K	Hold	10,000	–	–	0.1%	237
2024 Q2	$124K	Hold	10,000	–	–	0.05%	317
2024 Q1	$203K	Buy	+10,000	New	+$230K	0.1%	257

Other funds holding FLNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Empirical Asset Management's FLNA Position: Q3 2025 in Review

Empirical Asset Management sold out of Filana Therapeutics (FLNA) in Q3 2025, closing a stake of 10,000 shares — an estimated $18.1K sold.

Empirical Asset Management first reported a position in FLNA in Q1 2024 and held it in 6 quarters. The position peaked at $294K in Q3 2024. 103 funds tracked by Wall St. Rank hold FLNA as of Q3 2025.

Empirical Asset Management reported no remaining Filana Therapeutics position as of Q3 2025 after selling out during the quarter.
Empirical Asset Management sold 10,000 Filana Therapeutics shares in Q3 2025, an estimated $18.1K.
Empirical Asset Management first reported a position in Filana Therapeutics in Q1 2024 and held it in 6 quarters.
Empirical Asset Management's Filana Therapeutics position peaked at $294K in Q3 2024.
103 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2025.

Based on Empirical Asset Management's 13F filing for Q3 2025, filed 12 Nov 2025.